Brinker Capital Investments LLC Sells 4,757 Shares of Meridian Bioscience, Inc. (NASDAQ:VIVO)

Brinker Capital Investments LLC lowered its holdings in shares of Meridian Bioscience, Inc. (NASDAQ:VIVOGet Rating) by 12.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,225 shares of the company’s stock after selling 4,757 shares during the quarter. Brinker Capital Investments LLC’s holdings in Meridian Bioscience were worth $1,016,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in VIVO. JPMorgan Chase & Co. lifted its holdings in shares of Meridian Bioscience by 16.1% in the 1st quarter. JPMorgan Chase & Co. now owns 156,631 shares of the company’s stock worth $4,067,000 after acquiring an additional 21,777 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Meridian Bioscience by 11.1% in the 1st quarter. American Century Companies Inc. now owns 54,644 shares of the company’s stock worth $1,419,000 after acquiring an additional 5,463 shares during the last quarter. Citigroup Inc. lifted its holdings in shares of Meridian Bioscience by 2.5% in the 1st quarter. Citigroup Inc. now owns 48,835 shares of the company’s stock worth $1,268,000 after acquiring an additional 1,200 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Meridian Bioscience by 7.2% in the 1st quarter. Bank of Montreal Can now owns 14,144 shares of the company’s stock worth $383,000 after acquiring an additional 955 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in shares of Meridian Bioscience by 57.9% in the 1st quarter. MetLife Investment Management LLC now owns 23,227 shares of the company’s stock worth $603,000 after acquiring an additional 8,516 shares during the last quarter. Institutional investors own 89.72% of the company’s stock.

Meridian Bioscience Trading Up 0.3 %

Shares of VIVO opened at $33.74 on Monday. Meridian Bioscience, Inc. has a 1-year low of $19.91 and a 1-year high of $34.38. The company has a 50-day moving average of $32.74 and a 200 day moving average of $32.44. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of 34.78 and a beta of 0.26. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.63 and a quick ratio of 2.46.

Meridian Bioscience (NASDAQ:VIVOGet Rating) last announced its quarterly earnings data on Tuesday, November 22nd. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.05. Meridian Bioscience had a net margin of 12.70% and a return on equity of 16.74%. The company had revenue of $65.68 million during the quarter, compared to analyst estimates of $67.45 million. On average, research analysts expect that Meridian Bioscience, Inc. will post 0.83 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. William Blair reiterated a “market perform” rating on shares of Meridian Bioscience in a report on Friday, November 25th. StockNews.com lowered shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Saturday, November 19th.

Meridian Bioscience Company Profile

(Get Rating)

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.

Featured Stories

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVOGet Rating).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.